Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Global Device Approvals Snapshot: 25 June-1 July 2019

Executive Summary

A snapshot of global medical device approvals captured during the past week in Medtech Insight's Approvals Tracker. The week of 25 June to 1 July was another slow one for approvals, with no new PMAs, panel-track PMA supplements, or de novos. Japan’s MHLW approved Foundation Medicine’s companion diagnostic for Roche’s cancer drug Rozlytrek.

You may also be interested in...



Roche Beats Rivals To Japan Tumor-Agnostic Market With World-First Rozlytrek Nod

Roche’s tumor-agnostic drug receives first approval globally in Japan following an expedited review, giving the Swiss group a lead over its rival in this market. But sales may be limited.

IBM Divests Watson Health Assets To Focus On Cloud And AI Businesses

Investment firm Francisco Partners will acquire IBM’s Watson Health’s data and analytics assets – including Micromedex, MarketScan, and Clinical Development – for an undisclosed price.

Acutus Cuts Jobs To Reduce Cash Burn, Drive Adoption Of Cardiac Mapping System

The electrophysiology company announced it will reduce its workforce and take other cost-reduction measures to reduce its annual spending by $23m-$25m. Analysts suspect the company will need to raise more money from investors in 2022 or try to be acquired by a larger company.

Topics

Related Companies

UsernamePublicRestriction

Register

MT125311

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel